ovarian cancer
Conditions
Interventions
Case series:Albumin-bound paclitaxel?Nedaplatin
Sponsors
cancer Hospital Chinese Academy of Medical Science
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients with advanced ovarian epithelial cancer/fallopian tube cancer/primary peritoneal cancer who have relapsed with cisplatin/carboplatin resistance have not used albumin paclitaxel and/or nedaplatin in previous chemotherapy and are not primary platinum resistant; 2. Aged 18-70 years old; ECOG physical score 0-2 points; 3. Pathologically confirmed as epithelial cancer, and FIGO stage II-IV; 4. According to the RECIST 1.1 standard, it has clinically assessable lesions with a maximum diameter of metastatic lesions >=1 cm and lymph node metastasis of >=1.5 cm; and the target lesion is not suitable for surgical treatment; 5. Expected survival time is more than 4 months; 6. The main organ functions are normal, including but not limited to normal bone marrow function, liver and kidney function in accordance with chemotherapy indicators: (1) White blood cell count >=4 *10^9/L; (2) Neutrophil count >=2.0*10^9/L; (3) hemoglobin count >=90 g/L; (4) Platelet count >=100 *10^9/L; (5) ALT / AST=60 ml / min; 7. No long-term history of allergies, no allergy to the ingredients and ingredients of albumin-bound paclitaxel and nedaplatin; 8. No metastatic lesions in the brain; 9. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with primary platinum resistance, that is, patients with disease progression during the first use of platinum-containing chemotherapy; 2. Metastatic lesions in the central nervous system; 3. People who are in active infection and are not easy to control; 4. Patients with severe cardiopulmonary dysfunction and poor general condition, who cannot tolerate chemotherapy; 5. Those who cannot control pericardial effusion; 6. Patients with other tumors or previous history of other malignant tumors; 7. People who are receiving immunotherapy or endocrine therapy; 8. Pregnant and lactating women and those who are likely to become pregnant but do not wish to use appropriate contraceptive measures; 9. People with difficult-to-control mental illness; 10. Patients with allergic constitution; 11. Other circumstances that the investigator determined could not be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free survival;disease control rate;Overall survival;security; | — |
Countries
China
Contacts
Public ContactYuanguang Meng
Cancer Hospital Chinese Academy of Medical Sciences
Outcome results
None listed